Developer docs
API playgroundTry for free, no card

Search company profiles

Link Healthcare

Full company profile

uuid000thf8

Namestring
Link Healthcare
Legal namestring
Link Medical Products Pty Ltd
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Link Healthcare (legally Link Medical Products Pty Ltd) is an Australian specialty pharmaceutical company founded in 1997 that provides ethical, compliant access to both registered and unregistered specialty medicines across the Australasia, Asia, and Africa (AAA) region. The company sells a portfolio of over 20 registered pharmaceutical products spanning 13+ therapeutic areas—including oncology (ETOPHOS, VEPESID, HYDREA, NATULAN, TRECONDI), haematology, emergency medicine, analgesia/anaesthesia, dermatology, infectious diseases, intensive care, neurology, palliative care, psychiatry, and transplantation—and operates an unregistered medicine access platform covering clinical trial supply, Early Access Programs, medicine shortage sourcing, and discontinued product supply. Underpinning this is in-house pharmacovigilance and regulatory affairs capabilities that enable product licensing and safety monitoring across multiple jurisdictions, including Australia, New Zealand, Japan, Singapore, Hong Kong, and South Africa.

The company's customers are hospitals and healthcare institutions, individual healthcare professionals (prescribers), and pharmaceutical and biotechnology manufacturers seeking regional distribution or clinical trial supply support. Revenue is generated through sale of registered pharmaceutical products (one-time licensing style transactions), facilitation of unregistered medicine supply (licensing/royalty arrangements), and clinical services such as clinical trial supply and Early Access Programs. The company uses a sales-led go-to-market model with direct relationships supported by Australian-registered pharmacist-led medical information services, distributing primarily through direct hospital supply and pharmacy distribution channels. Specific pricing is not publicly disclosed, with prices determined via healthcare system reimbursement and prescription pathways. Link Healthcare has operated as a wholly-owned subsidiary of Clinigen Group since 2015, with the Link Australasia team numbering over 45 employees and headquarters in Warriewood, Sydney.

Short descriptiontext

Link Healthcare is an Australian specialty pharmaceutical company (founded 1997, Clinigen Group subsidiary) that provides ethical access to over 20 registered and unregistered specialty medicines across oncology, haematology, emergency, and other therapeutic areas to hospitals, prescribers, and pharma partners in the Australasia, Asia, and Africa region.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, unregistered medicine access, clinical trial supply, early access programs, oncology medicines
Industry4 codes
1Specialty Care Pharmaceuticals
CodeHLAIAAABPrimaryYes
2Specialty Pharmacies (Complex/High-Cost Therapies)
CodeHLAFALACPrimaryNo
3Specialty Injectable & Infusion Therapies (Cross-therapeutic)
CodeHLAIACAOPrimaryNo
4Generic Hospital & Institutional Products
CodeHLAIABALPrimaryNo
NAICS code1 code
  • Health Care and Social Assistance62
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Services-Health Services8000
Product category
Specialty Pharmaceuticals Distribution
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Registered Pharmaceutical Products
TypeOne Time License
Description

Sale and distribution of registered specialty medicines in diverse therapeutic areas including oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry and transplantation.

linkhealthcare.com.au
2Unregistered Medicine Supply
TypeLicensing Royalties
Description

Facilitating ethical access to unregistered or commercially unavailable medicines, addressing clinical trial supply, global unavailability, medicine shortages, and discontinued products.

linkhealthcare.com.au
3Clinical Services
TypeProfessional Services
Description

Services including clinical trial supplies, Early Access Programs, and sourcing medicines for shortages for pharmaceutical and biotech companies.

linkhealthcare.com.au
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Link Healthcare supplies registered specialty pharmaceutical products across 13 therapeutic areas (oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry, transplantation) and provides ethical, compliant access to unregistered or commercially unavailable medicines, including clinical trial supply, Early Access Programs, and medicine shortage sourcing. It serves hospitals, healthcare professionals, and pharmaceutical/biotech partners across the Australasia, Asia and Africa (AAA) region as part of Clinigen Group.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Link Healthcare is a specialty pharmaceutical company that provides access to both registered and unregistered medicines. The product portfolio consists of over 20 registered pharmaceutical products across diverse therapeutic areas including oncology (ETOPHOS, VEPESID, HYDREA, NATULAN, TRECONDI), haematology (MERCAPTOPURINE-LINK, ALLMERCAP, KAMRAB), emergency medicine (ACETYLCYSTEINE-LINK INJECTION, ADRENALINE-LINK, PENTOTHAL), analgesia/anaesthesia (PENTOTHAL), dermatology (DAPSONE), endocrinology, infectious diseases (FOSCAVIR), intensive care, rheumatology, neurology (MYSOLINE, IMUKIN), palliative care, psychiatry, and transplantation. These products are complemented by services including clinical trial supply, Early Access Programs, unregistered medicine supply, and medicine shortage sourcing. The company operates as part of Clinigen Group and supports healthcare professionals and pharmaceutical industry partners across Australasia.

Product and service6 records
1ACETYLCYSTEINE-LINK INJECTION
CategoryRegistered Pharmaceutical Product
Description

A specialist injection product containing acetylcysteine, used for treating paracetamol overdose and as a mucolytic agent. It is a registered pharmaceutical product distributed to hospitals and healthcare institutions in Australia.

2ADRENALINE-LINK
CategoryRegistered Pharmaceutical Product
Description

Contains adrenaline (epinephrine) acid tartrate, used for emergency treatment of anaphylaxis and cardiac arrest. It is a registered pharmaceutical product supplied to hospitals and emergency care settings.

3ALLMERCAP
CategoryRegistered Pharmaceutical Product
Description

Contains mercaptopurine monohydrate, used in the treatment of leukemia and inflammatory bowel disease. It is a registered pharmaceutical product.

4ATACAND
CategoryRegistered Pharmaceutical Product
Description

Contains Candesartan cilexetil, an angiotensin II receptor antagonist used to treat hypertension and heart failure. It is a registered pharmaceutical product.

5ATACAND PLUS
CategoryRegistered Pharmaceutical Product
Description

Combination product with Hydrochlorothiazide and Candesartan cilexetil, used for treating hypertension. It is a registered pharmaceutical product.

6DAPSONE
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Link Healthcare became part of Clinigen in 2015, significantly strengthening the Group's global presence and position in the AAA (Australasia, Asia and Africa) region. Clinigen is a rapidly growing specialty pharmaceutical and services company focused on delivering the right medicine, to the right patient, at the right time.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strong partnerships with biotechnology companies across the globe, providing access to specialist medicines and novel pharmaceuticals for the Australasian region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnerships with pharmaceutical manufacturers for supply and distribution of specialist registered and unregistered medicines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner agreements with suppliers across the globe reviewed regularly to allow supply of products into new geographic regions, reflecting commitment to providing a global network of products and services.

5Equity Pharmaceutical Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Merger with South Africa's Equity Pharmaceutical group conducted over 2010-2013, expanding geographic presence and product portfolio.

linkhealthcare.com.au
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based specialty pharma services company providing named-patient access, early access programs and unlicensed medicine supply globally. Closely comparable business model and service offering to Link's unregistered medicine services, with shared pharma/biotech client base.

TypeDirect peer
Description

Parent company and global leader in ethical access to unregistered and specialty medicines. Directly comparable in services (Early Access Programs, clinical trial supply, managed access) and product distribution model; Link is the AAA-region arm of Clinigen's network.

TypeOthers
Description

Global provider of regulatory affairs, pharmacovigilance and quality compliance services to pharma and biotech. Comparable in delivering the in-house regulatory and pharmacovigilance infrastructure (one of Link's stated capabilities) on an outsourced basis to similar clients.

4Econdisc (an Idis Group company)
TypeDirect peer
Description

Specialist pharmaceutical company providing named-patient supply, early access and clinical trial supply globally. Closely comparable services model to Link's unregistered medicine access and clinical trial supply offerings, with shared hospital and HCP customer base.

TypeDirect peer
Description

UK-based pharmaceutical distributor specialising in unlicensed medicines, clinical trial supply and global access programs. Comparable in distributing hard-to-source, unlicensed and clinical-trial medicines to hospitals and HCPs across multiple jurisdictions.

TypeRegional player
Description

South African-headquartered specialty and generic pharmaceutical group with presence across Africa, Australasia and Asia. Comparable in regional multi-market presence (including South Africa, an AAA overlap with Link post-Equity Pharmaceutical merger) and in-licensed mature product strategy.

TypeDirect peer
Description

UK-based specialist pharmaceutical distributor and access provider for unlicensed, imported, and clinical-trial medicines. Directly comparable in supplying hard-to-source and unregistered medicines to hospitals and HCPs, with similar regulatory and pharmacovigilance infrastructure.

TypeBroad incumbent
Description

European-listed specialty biopharma focused on rare diseases and specialty medicines with global commercial reach. Comparable in operating a specialty pharma model centred on niche, high-medical-need therapeutics and global partner-led access.

TypeRegional player
Description

Australia-headquartered specialty pharmaceutical company with branded and generic products, complex generics and specialty distribution. Comparable in Australian-domiciled specialty pharma focus and in-licensing-led portfolio growth model.

TypeDirect peer
Description

UK-based unlicensed and specials medicines manufacturer and distributor serving hospital pharmacies. Comparable in providing ethical access to medicines not commercially available, including specials manufacturing, clinical trial supply and shortage-sourcing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Link Healthcare

Specialty Pharmaceuticals Distributionlinkhealthcare.com.au

Link Healthcare is an Australian specialty pharmaceutical company (founded 1997, Clinigen Group subsidiary) that provides ethical access to over 20 registered and unregistered specialty medicines across oncology, haematology, emergency, and other therapeutic areas to hospitals, prescribers, and pharma partners in the Australasia, Asia, and Africa region.

What Link Healthcare does

Link Healthcare (legally Link Medical Products Pty Ltd) is an Australian specialty pharmaceutical company founded in 1997 that provides ethical, compliant access to both registered and unregistered specialty medicines across the Australasia, Asia, and Africa (AAA) region. The company sells a portfolio of over 20 registered pharmaceutical products spanning 13+ therapeutic areas—including oncology (ETOPHOS, VEPESID, HYDREA, NATULAN, TRECONDI), haematology, emergency medicine, analgesia/anaesthesia, dermatology, infectious diseases, intensive care, neurology, palliative care, psychiatry, and transplantation—and operates an unregistered medicine access platform covering clinical trial supply, Early Access Programs, medicine shortage sourcing, and discontinued product supply. Underpinning this is in-house pharmacovigilance and regulatory affairs capabilities that enable product licensing and safety monitoring across multiple jurisdictions, including Australia, New Zealand, Japan, Singapore, Hong Kong, and South Africa.

The company's customers are hospitals and healthcare institutions, individual healthcare professionals (prescribers), and pharmaceutical and biotechnology manufacturers seeking regional distribution or clinical trial supply support. Revenue is generated through sale of registered pharmaceutical products (one-time licensing style transactions), facilitation of unregistered medicine supply (licensing/royalty arrangements), and clinical services such as clinical trial supply and Early Access Programs. The company uses a sales-led go-to-market model with direct relationships supported by Australian-registered pharmacist-led medical information services, distributing primarily through direct hospital supply and pharmacy distribution channels. Specific pricing is not publicly disclosed, with prices determined via healthcare system reimbursement and prescription pathways. Link Healthcare has operated as a wholly-owned subsidiary of Clinigen Group since 2015, with the Link Australasia team numbering over 45 employees and headquarters in Warriewood, Sydney.

Link Healthcare firmographics

Firmographics
Name
Link Healthcare
Legal name
Link Medical Products Pty Ltd
Website
https://linkhealthcare.com.au
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Link Healthcare is an Australian specialty pharmaceutical company (founded 1997, Clinigen Group subsidiary) that provides ethical access to over 20 registered and unregistered specialty medicines across oncology, haematology, emergency, and other therapeutic areas to hospitals, prescribers, and pharma partners in the Australasia, Asia, and Africa region.
Ownership category
akta.pro rank

Link Healthcare industry classification

Industry
Product category
Specialty Pharmaceuticals Distribution
NAICS
Health Care and Social Assistance (62)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Health Services (8000)
akta.pro primary industry
Specialty Care Pharmaceuticals (HLAIAAAB)
akta.pro secondary industries
Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

  • Specialty pharmaceuticals
  • Unregistered medicine access
  • Clinical trial supply
  • Early access programs
  • Oncology medicines

Where Link Healthcare is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Link Healthcare business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Registered Pharmaceutical Products: Sale and distribution of registered specialty medicines in diverse therapeutic areas including oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry and transplantation.
  2. Unregistered Medicine Supply: Facilitating ethical access to unregistered or commercially unavailable medicines, addressing clinical trial supply, global unavailability, medicine shortages, and discontinued products.
  3. Clinical Services: Services including clinical trial supplies, Early Access Programs, and sourcing medicines for shortages for pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Link Healthcare product offering

Product offering

Core offering

Link Healthcare supplies registered specialty pharmaceutical products across 13 therapeutic areas (oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry, transplantation) and provides ethical, compliant access to unregistered or commercially unavailable medicines, including clinical trial supply, Early Access Programs, and medicine shortage sourcing. It serves hospitals, healthcare professionals, and pharmaceutical/biotech partners across the Australasia, Asia and Africa (AAA) region as part of Clinigen Group.

Product overview

Link Healthcare is a specialty pharmaceutical company that provides access to both registered and unregistered medicines. The product portfolio consists of over 20 registered pharmaceutical products across diverse therapeutic areas including oncology (ETOPHOS, VEPESID, HYDREA, NATULAN, TRECONDI), haematology (MERCAPTOPURINE-LINK, ALLMERCAP, KAMRAB), emergency medicine (ACETYLCYSTEINE-LINK INJECTION, ADRENALINE-LINK, PENTOTHAL), analgesia/anaesthesia (PENTOTHAL), dermatology (DAPSONE), endocrinology, infectious diseases (FOSCAVIR), intensive care, rheumatology, neurology (MYSOLINE, IMUKIN), palliative care, psychiatry, and transplantation. These products are complemented by services including clinical trial supply, Early Access Programs, unregistered medicine supply, and medicine shortage sourcing. The company operates as part of Clinigen Group and supports healthcare professionals and pharmaceutical industry partners across Australasia.

Differentiator

Problem solved

Functional benefit

Products and services

  • ACETYLCYSTEINE-LINK INJECTION A specialist injection product containing acetylcysteine, used for treating paracetamol overdose and as a mucolytic agent. It is a registered pharmaceutical product distributed to hospitals and healthcare institutions in Australia.
  • ADRENALINE-LINK Contains adrenaline (epinephrine) acid tartrate, used for emergency treatment of anaphylaxis and cardiac arrest. It is a registered pharmaceutical product supplied to hospitals and emergency care settings.
  • ALLMERCAP Contains mercaptopurine monohydrate, used in the treatment of leukemia and inflammatory bowel disease. It is a registered pharmaceutical product.
  • ATACAND Contains Candesartan cilexetil, an angiotensin II receptor antagonist used to treat hypertension and heart failure. It is a registered pharmaceutical product.
  • ATACAND PLUS Combination product with Hydrochlorothiazide and Candesartan cilexetil, used for treating hypertension. It is a registered pharmaceutical product.
  • DAPSONE

Companies that use Link Healthcare

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Link Healthcare technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Link Healthcare partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • Clinigen GroupflagshipStrategic or Co-development PartnerLink Healthcare became part of Clinigen in 2015, significantly strengthening the Group's global presence and position in the AAA (Australasia, Asia and Africa) region. Clinigen is a rapidly growing specialty pharmaceutical and services company focused on delivering the right medicine, to the right patient, at the right time.
  • Biotechnology CompaniescoreStrategic or Co-development PartnerStrong partnerships with biotechnology companies across the globe, providing access to specialist medicines and novel pharmaceuticals for the Australasian region.
  • Pharmaceutical ManufacturerscoreStrategic or Co-development PartnerPartnerships with pharmaceutical manufacturers for supply and distribution of specialist registered and unregistered medicines.
  • Global Pharmaceutical SupplierscoreStrategic or Co-development PartnerPartner agreements with suppliers across the globe reviewed regularly to allow supply of products into new geographic regions, reflecting commitment to providing a global network of products and services.
  • Equity Pharmaceutical GroupcoreStrategic or Co-development PartnerMerger with South Africa's Equity Pharmaceutical group conducted over 2010-2013, expanding geographic presence and product portfolio.

Scale indicators4 records

Recent moves12 records

Expansion highlights4 records

Link Healthcare competitors and assessment

Company assessment

Direct peers

  • Tanner Pharma Group: US-based specialty pharma services company providing named-patient access, early access programs and unlicensed medicine supply globally. Closely comparable business model and service offering to Link's unregistered medicine services, with shared pharma/biotech client base.
  • Clinigen Group: Parent company and global leader in ethical access to unregistered and specialty medicines. Directly comparable in services (Early Access Programs, clinical trial supply, managed access) and product distribution model; Link is the AAA-region arm of Clinigen's network.
  • Econdisc (an Idis Group company): Specialist pharmaceutical company providing named-patient supply, early access and clinical trial supply globally. Closely comparable services model to Link's unregistered medicine access and clinical trial supply offerings, with shared hospital and HCP customer base.
  • Durbin PLC: UK-based pharmaceutical distributor specialising in unlicensed medicines, clinical trial supply and global access programs. Comparable in distributing hard-to-source, unlicensed and clinical-trial medicines to hospitals and HCPs across multiple jurisdictions.
  • Mawdsley-Brooks & Co: UK-based specialist pharmaceutical distributor and access provider for unlicensed, imported, and clinical-trial medicines. Directly comparable in supplying hard-to-source and unregistered medicines to hospitals and HCPs, with similar regulatory and pharmacovigilance infrastructure.
  • Quantum Pharmaceutical: UK-based unlicensed and specials medicines manufacturer and distributor serving hospital pharmacies. Comparable in providing ethical access to medicines not commercially available, including specials manufacturing, clinical trial supply and shortage-sourcing.

Others

  • PharmaLex: Global provider of regulatory affairs, pharmacovigilance and quality compliance services to pharma and biotech. Comparable in delivering the in-house regulatory and pharmacovigilance infrastructure (one of Link's stated capabilities) on an outsourced basis to similar clients.

Regional players

  • Aspen Pharmacare: South African-headquartered specialty and generic pharmaceutical group with presence across Africa, Australasia and Asia. Comparable in regional multi-market presence (including South Africa, an AAA overlap with Link post-Equity Pharmaceutical merger) and in-licensed mature product strategy.
  • Mayne Pharma: Australia-headquartered specialty pharmaceutical company with branded and generic products, complex generics and specialty distribution. Comparable in Australian-domiciled specialty pharma focus and in-licensing-led portfolio growth model.

Broad incumbents

  • Swedish Orphan Biovitrum (Sobi): European-listed specialty biopharma focused on rare diseases and specialty medicines with global commercial reach. Comparable in operating a specialty pharma model centred on niche, high-medical-need therapeutics and global partner-led access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Link Healthcare social profiles

Digital presence

Link Healthcare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Link Healthcare leadership team

Management profile

Number of profiles

Link Healthcare funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Link Healthcare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Link Healthcare

What does Link Healthcare do?

Link Healthcare supplies registered specialty pharmaceutical products across 13 therapeutic areas (oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry, transplantation) and provides ethical, compliant access to unregistered or commercially unavailable medicines, including clinical trial supply, Early Access Programs, and medicine shortage sourcing. It serves hospitals, healthcare professionals, and pharmaceutical/biotech partners across the Australasia, Asia and Africa (AAA) region as part of Clinigen Group.

Is Link Healthcare a public or private company?

Link Healthcare is a private company. It is classified as corporate owned and is currently operating.

When was Link Healthcare founded?

Link Healthcare was founded in 1997. It employs 11 to 50 people.

Where is Link Healthcare based?

Link Healthcare is headquartered in Sydney, Australia, in the Oceania region.

How does Link Healthcare make money?

Three revenue lines are on record. Registered Pharmaceutical Products are the primary driver. The others are unregistered Medicine Supply and clinical Services.

Who are Link Healthcare's main competitors?

Direct peers on record are Tanner Pharma Group, Clinigen Group, Econdisc (an Idis Group company), Durbin PLC, Mawdsley-Brooks & Co and Quantum Pharmaceutical. PharmaLex is listed as an others. Regional players are Aspen Pharmacare and Mayne Pharma. Swedish Orphan Biovitrum (Sobi) is listed as a broad incumbent.

Does Link Healthcare have an API?

No public API is recorded for Link Healthcare.

What industry is Link Healthcare in?

Link Healthcare's product category is Specialty Pharmaceuticals Distribution. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies). Its NAICS code is 62 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales